Reduction of sCD163

The secondary outcome of the study was the reduction in sCD163. Whilst I am no biologist, there seems to be common thread that BIT (BIT225) is more than just for HIV and it centres around the reduction in sCD163.

BIT has mentioned Dengue, and you can see the below link talks about sCD163 and Dengue.

Dengue potentially will be bigger earner for BIT than HIV (HIV will be massive). BIT has also referenced other virus like Zika and Influenza.

Maybe I’m getting overly excited, but has BIT stumbled onto something truely massive?

I would love someone smarter than me to explain what are the true implications here.

BIT has consistently turned over 50 million shares since the announcement, and the share trading action just points to something massive IMHO.

——-

In addition to the beneficial immunological effects, there was a significant reduction in the level of the macrophage activation marker sCD163 in the BIT225-treated population by the end of the treatment period. Higher levels of sCD163 are linked with worse clinical outcomes in patients. This reduction of sCD163 by BIT225 may provide additional clinical benefit in these patients.


https://www.sciencedirect.com/science/article/pii/S1386653216305558

Highlights


•
The current study proposed the importance of sCD163, a macrophage activation marker in dengue.

•
The sCD163 levels are significantly elevated during the defervescence stage of dengue disease